Commercial Novo’s CEO champions “record-breaking start” for Wegovy pill in US market Pharmaceutical TechnologyNovo Nordisk's Wegovy pill is already providing financial fuel in the company's bid to catch Eli Lilly.Metabolic & GLP-1Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) Pharmaceutical Technology Novo Nordisk’s Wegovy pill is already providing financial fuel in the company’s bid to catch Eli Lilly. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Angelini inks $4.1B Catalyst buy to enter US rare disease marketNext: Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq Related Stories Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026 Commercial Lilly launches its LillyDirect sales channel in the UK pharminent June 25, 2026
